Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Zhejiang Tianyu Pharmaceutical Co., Ltd.
WARNING LETTER
•Zhejiang Tianyu Pharmaceutical Co., Ltd.•March 4, 2022

Zhejiang Tianyu Pharmaceutical Co., Ltd. – FDA Warning Letter, Mar 4, 2022

Record Details

The FDA inspected Zhejiang Tianyu Pharmaceutical Co., Ltd. from February 28 to March 4, 2022, identifying significant deviations from current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API), rendering their API adulterated.

Key violations include: 1. **Failure to extend investigations:** The firm did not adequately investigate a (b)(4) impurity in (b)(4) API, limiting testing to a fraction of affected lots and failing to include lots manufactured as early as 2017. They also continued to release and distribute API without mitigating controls despite knowing of the impurity risk. 2. **Failure to establish impurity profiles:** The firm failed to systematically evaluate manufacturing processes to identify potential impurities like (b)(4) in (b)(4) API and (b)(4) in (b)(4) starting material, despite customer complaints and external notifications. This led to the release of 39 lots for the U.S. market with unacceptable (b)(4) impurity levels. 3. **Failure to clean equipment at appropriate intervals:** Equipment used in (b)(4) synthesis had visible residues (brownish rust-like and thick black spots) on product contact surfaces, indicating inadequate cleaning. A complaint investigation linked this to out-of-specification (b)(4) impurity in a returned lot. 4. **Repeat deviation - Cleaning validation:** The firm failed to complete cleaning validation studies

Company
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Inspection date
March 4, 2022
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 4bf61b57-f3c3-4cdb-a2ad-127f6250cdad

Violation Codes5
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)21 CFR 21121 U.S.C. 356C(b)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Other documents for Zhejiang Tianyu Pharmaceutical Co., Ltd.
  • 483 - 2024-11-29November 29, 2024
  • EIR - 2022-03-04March 4, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Tianyu Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.